Rubric Capital Management LP: TEVA PHARMACEUTICAL INDS LTD (TEVA): Quarterly 13F Position History
As of Q1 2026, Rubric Capital Management LP reported 15,250,000 shares of TEVA PHARMACEUTICAL INDS LTD (TEVA), worth $459.3M and representing 5.6% of its 13F equity book. Quarter-over-quarter share count change: 6,105,510 (-28.6%) . The position first appeared in Q4 2018 and has been disclosed across 30 13F-HR filings in Pactolio's tracked window.
- 15,250,000Shares Held (Latest Filing)
- $459.3MReported Market Value (Latest Filing)
- 5.6%Portfolio Weight (% of 13F Equity Book)
- 6,105,510Quarter-over-Quarter Share Change
- -$207.2MQuarter-over-Quarter Value Change
- 26,000,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 30 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 15,250,000 | 6,105,510 | -28.6% | $459.3M | 5.6% | $30.1 |
| Q4 2025 | 21,355,510 | 3,294,490 | -13.4% | $666.5M | 8.0% | $31.2 |
| Q3 2025 | 24,650,000 | 1,350,000 | -5.2% | $497.9M | 6.7% | $20.2 |
| Q2 2025 | 26,000,000 | +450,000 | +1.8% | $435.8M | 7.0% | $16.8 |
| Q1 2025 | 25,550,000 | +8,550,000 | +50.3% | $392.7M | 7.0% | $15.4 |
| Q4 2024 | 17,000,000 | +994,502 | +6.2% | $374.7M | 6.8% | $22.0 |
| Q3 2024 | 16,005,498 | 1,256,243 | -7.3% | $288.4M | 4.7% | $18.0 |
| Q2 2024 | 17,261,741 | 407,847 | -2.3% | $280.5M | 7.4% | $16.3 |
| Q1 2024 | 17,669,588 | 557,013 | -3.1% | $249.3M | 7.4% | $14.1 |
| Q4 2023 | 18,226,601 | 773,399 | -4.1% | $190.3M | 7.1% | $10.4 |
| Q3 2023 | 19,000,000 | +281,638 | +1.5% | $193.8M | 8.2% | $10.2 |
| Q2 2023 | 18,718,362 | +14,218,556 | +316.0% | $140.9M | 6.0% | $7.5 |
| Q1 2023 | 4,499,806 | +4,499,806 | — | $39.8M | 1.6% | $8.8 |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2019 | 0 | 830,000 | -100.0% | $0 | 0.0% | — |
| Q4 2018 | 830,000 | — | — | $12.8M | 1.6% | $15.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Rubric Capital Management LP first disclose a TEVA position in 13F-HR filings?
Rubric Capital Management LP first reported TEVA PHARMACEUTICAL INDS LTD (TEVA) on its 13F-HR filing for the period ending 2018-12-31 (Q4 2018). The position has appeared on 30 reported quarters within Pactolio's tracked window.
What was Rubric Capital Management LP's most recent quarter-over-quarter share-count change in TEVA?
Between Q4 2025 and Q1 2026, Rubric Capital Management LP reduced its TEVA position by 6,105,510 shares (-28.6%), leaving 15,250,000 shares at a market value of $459.3M.
Does the implied price-per-share represent Rubric Capital Management LP's cost basis in TEVA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.